Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0K5KS
|
|||
| Former ID |
DAP000392
|
|||
| Drug Name |
Adalimumab
|
|||
| Synonyms |
Humira; Adalimumab (genetical recombination); Humira (TN); Adalimumab (USAN/INN); Adalimumab (genetical recombination) (JAN)
Click to Show/Hide
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Rheumatoid arthritis [ICD-11: FA20] | Approved | [1], [2] | |
| Therapeutic Class |
Antirheumatic Agents
|
|||
| Company |
Abbott Laboratories
|
|||
| PubChem Substance ID | ||||
| ADReCS Drug ID | BADD_D00041 | |||
| SuperDrug ATC ID |
L04AB04
|
|||
| Interaction between the Drug and Microbe | Top | |||
|---|---|---|---|---|
| The Abundace of Studied Microbe(s) Regulated by Drug | ||||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Acidaminococcales | ||||
|
Studied Microbe: Phascolarctobacterium
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | Human | Experimental Sample | Intestinal sample | |
| Disease or Condition | Crohn disease | |||
| Description | The abundance of Phascolarctobacterium was decreased by Adalimumab. | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Bifidobacteriales | ||||
|
Studied Microbe: Bifidobacterium
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Intestinal sample | |
| Disease or Condition | Crohn disease | |||
| Description | The abundance of Bifidobacterium was increased by Adalimumab. | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Coriobacteriales | ||||
|
Studied Microbe: Collinsella
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Intestinal sample | |
| Disease or Condition | Crohn disease | |||
| Description | The abundance of Collinsella was increased by Adalimumab. | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Eggerthellales | ||||
|
Studied Microbe: Eggerthella
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Intestinal sample | |
| Disease or Condition | Crohn disease | |||
| Description | The abundance of Eggerthella was increased by Adalimumab. | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Enterobacterales | ||||
|
Studied Microbe: Escherichia coli
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | Human | Experimental Sample | Rectum mucosa | |
| Disease or Condition | Crohn disease | |||
| Description | The abundance of Escherichia coli was decreased by Adalimumab (p < 0.05). | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Eubacteriales | ||||
|
Studied Microbe: Faecalibacterium prausnitzii
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Ulcerative colitis | |||
| Description | The abundance of Faecalibacterium prausnitzii was increased by Adalimumab. | |||
|
Studied Microbe: Lachnospira
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Intestinal sample | |
| Disease or Condition | Crohn disease | |||
| Description | The abundance of Lachnospira was increased by Adalimumab. | |||
|
Studied Microbe: Roseburia faecis
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Intestinal sample | |
| Disease or Condition | Crohn disease | |||
| Description | The abundance of Roseburia faecis was increased by Adalimumab. | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Gut microbiota | ||||
|
Studied Microbe: Burkholderiales
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Abundance Change | Increase | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Rheumatoid arthritis | |||
| Description | The abundance of Burkholderiales was increased by Adalimumab. | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4860). | |||
| REF 2 | Molecular targets of rheumatoid arthritis. Inflamm Allergy Drug Targets. 2008 Mar;7(1):53-66. | |||
| REF 3 | Emerging Insights on the Interaction Between Anticancer and Immunosuppressant Drugs and Intestinal Microbiota in Pediatric Patients. Clin Transl Sci. 2020 Mar;13(2):238-259. | |||
| REF 4 | Anti-tumour Necrosis Factor Treatment with Adalimumab Induces Changes in the Microbiota of Crohn's Disease. J Crohns Colitis. 2015 Oct;9(10):899-906. | |||
| REF 5 | Adalimumab for psoriasis patients who are non-responders to etanercept: open-label prospective evaluation. J Eur Acad Dermatol Venereol. 2009 Dec;23(12):1394-7. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.